Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies

References

• Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006;129:104-15
   PubMed Web of Science ®Google Scholar
• Hayes D Jr, Meyer KC. Acute exacerbations of chronic bronchitis in elderly patients: pathogenesis, diagnosis and management. Drugs Aging 2007;24:555-72
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute. COPD Fact Sheet. Bethesda, MD: U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 03-5229. March 2003. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.pdf[Last accessed 8 June 2007]
   Google Scholar
• Halpern MT, Higashi MK, Bakst AW, et al. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review. J Manag Care Pharm 2003;9:353-9
   PubMedGoogle Scholar
• Halpern MT, Polzin J, Higashi MK, et al. The workplace impact of acute exacerbations of chronic bronchitis (AECB); a literature review. COPD 2004;1:249-54
   PubMedGoogle Scholar
• Schmier JK, Halpern MT, Higashi MK, et al. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res 2005;14:329-47
   PubMed Web of Science ®Google Scholar
• Sin DD, McAlister FA, Man SFP, et al. Contemporary management of chronic obstructive pulmonary disease. Scientific review. JAMA 2003;290:2301-12
   PubMed Web of Science ®Google Scholar
• Mahler DA, Donohue JF, Goldman MD, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65
   PubMed Web of Science ®Google Scholar
• Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:341-2
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-4
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-91
   PubMed Web of Science ®Google Scholar
• Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 µg)/Salmeterol (50 µg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-43
   PubMed Web of Science ®Google Scholar
• Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91
   PubMed Web of Science ®Google Scholar
• Donohue JF, Kalberg C, Emmett A, et al. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004;3:173-81
   PubMedGoogle Scholar
• Thirstrup S, Kampmann JP. Combined salmeterol and fluticasone for COPD. Lancet 2003;361:1650-1
   PubMed Web of Science ®Google Scholar
• MacAllister R. Combined salmeterol and fluticasone for COPD. Lancet 2003;361:1650-1
   Web of Science ®Google Scholar
• Complete Prescribing Information and Medication Guide for ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder). Available at:http://www.advair.com/ [Last accessed 8 June 2007]
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
   PubMed Web of Science ®Google Scholar
• Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, 2nd edn. Cary NC: SAS Institute Inc., 2000
   Google Scholar
• McCullagh P, Nelder JA. Generalized Linear Models. 2nd edn. London: Chapman and Hall, 1989
   Google Scholar
• Lipscomb J, Ancukiewicz M, Parmigiani G, et al. Predicting the cost of illness: a comparison of alternative models applied to stroke. Med Decis Making 1998;18(Suppl 2):S39-56
   PubMed Web of Science ®Google Scholar
• Ghali WA, Quan H, Brant R et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 2001;286:1494-7
   PubMed Web of Science ®Google Scholar
• Pasta DJ, Cisternas MG. Estimating Standard Errors for CLASS Variables in Generalized Linear Models Using PROC IML. SAS Users Group International (SUGI 28) Proceedings. March 30 – April 2, 2003. Seattle, Washington. Available at: http://www2.sas.com/proceedings/sugi28/Proceed.pdf [Last accessed December 2004]
   Google Scholar
• Efron B, Tibhirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993
   Google Scholar
• Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007;4:127-34
   PubMedGoogle Scholar
• Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Lewis CC, Fiscella RG, Kosty T. Need for greater scrutiny of days supply values in DACON calculations. J Manag Care Pharm 2004;10:172-3
   PubMedGoogle Scholar